Clinical Trial Update: An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Open-label Phase IIa/IIb trial evaluating VG161 as monotherapy and in combination with nivolumab for hepatocellular carcinoma or intrahepatic cholangiocarcinoma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• VG161
• nivolumab (nivolumab)

Snippet

Sponsor: Virogin Biotech Canada Ltd | Conditions: Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma | Phase 2 | Status: RECRUITING